

Public funding of research – EU perspective

Presented by: Stefanie Prilla European Medicines Agency





In this presentation

- Funding sources for research in health issues/medicines in Europe
- EC's 7th Framework Programme (FP7)
 - Scope
 - Priority areas for funding under the FP Health Theme
 - EMA & FP7
 - How to learn about calls
 - Application and selection procedure
 - Conditions for participation
- Now and beyond 2013

Funding research into health/medicines in Europe

- EC public funding current programming period: 2007-2013
 7th Framework Programme (FP7) 55 bn
 - European Regional Development Fund (ERDF) ⇒ Regional support in line with National Strategic Reference Frameworks 86 bn
- Public Private Partnerships: FP7 Joint Technology Initiatives
 - Innovative Medicines Initiative Joint Undertaking (IMI JU) 룾 2 bn
- National funding schemes
 - Example UK: Medical Research Council, National Institute for Health Research, etc



EC 7th Framework Programme (FP7)



- Set up by Decision of the European Parliament and the Council (1982/2006/EC) ⇒ 2007-2013
- Directorate-General for Research & Innovation (Directorate F Health)

Strategic Objectives:

- strengthen the scientific and technological base of European industry;
- encourage Europe's international competitiveness, while promoting research that supports EU policies.



差 4.7 bn

EC 7th Framework Programme (FP7)

 Co-finances research & technological development in the main areas of the EU research policy

Lifelong training

Specific actions

Industry-academia pathways

International dimension

• 5 building blocks

Cooperation


I deas People Capacities \mathbf{E} 6.1 bn overall \mathbf{E} 600-800 m per year

- Health
- Food, agriculture and fisheries, and biotechnology
- Information and communication technologies
- Nanosciences, nanotechnologies, materials and new production technologies
- Energy
- Environment (including climate change)
- Transport (including aeronautics)
- Socio-economic sciences and the humanities
- Space
- Security



Nuclear

Research



Activity 4: Support actions & response to EU policy needs

cross-cutting issues:

international cooperation, SMEs

•child health, ageing populations, gender-related health issues

(Special attention will also be given to communicating research outcomes and engaging in dialogue with civil society, in particular with patient groups.)

SEVENTH FRAMEWORN PROGRAMME

FP7 – Health Theme

Features in 2012 and 2013



2012 thematic priorities:	2013 thematic priorities:
Ageing	The brain
Medical technologies	Anti-microbial Resistance
Rare diseases / Personalised Medicines	
Healthcare systems	

EMA & EC's DG Research – funding safety studies

- List of priorities in drug safety research provided by EMA
 - Scope: class issues or off-patent substances
 - Characterisation of safety profile(s)
 - Consider public health impact of research:
 - ✓ Usage of the drug class
 - ✓ Seriousness of the safety issue
 - ✓ Possibility of obtaining comparative safety data
- Draft list discussed at PhVWP plenary; adopted by CHMP

Safety Research Topics proposed by EMA & included in FP7

Call:	Consortium	Title	Co-ordinator	Drugs studied
2 nd 2007	SOS	Cardiovascular and gastrointestinal safety of NSAIDs	Miriam CJM Sturkenboom, Erasmus Medical Centre	Traditional nonaspirin, nonsteroidal anti-inflammatory drugs *tNSAIDs) and cyclo-oxygenase II inhibitors (coxibs)
3 rd 2008	ARITMO	Arrhythmogenic potential of drugs	Miriam CJM Sturkenboom, Erasmus Medical Centre	Antipsychotics (ATC N05A), anti-infectives (antibacterials (J01) antimicotics (J02) and antivirals (J05) and H1-antihistamines
4 th 2009	ADDUCE	Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects	Ian Wong, School of Pharmacy, University of London	Methylphenidate
4 th	EURO- mediCAT	EUROmediCAT: Safety of Medication use in Pregnancy in Relation to Risk of Congenital Malformations	Helen Dolk, University of Ulster	New antiepileptics, insulin analogs, SSRI antidepressants, and antiasthmatics
4 th	PHARMA- CHILD	Long-term PHARMacovigilance for Adverse effects in childhood arthritis	Nico Wulffraat, University Medical Centre Utrecht	Immune modulatory drugs
4 th	STOP	Suicidality: Treatment Occurring in Paediatrics	Paramala J Santosh, University College London, Institute of Child Health	Risperidone in conduct disorder, fluoxetine in depression, and montelukast in bronchial asthma
Under	negotiation	Total fu	Inding volume s	so far: 毛 18 m; 差 3 m each
5 th 2010				Cancer risk and insulin analogues
5th				Safety of anti-diabetes drugs (cardio/cerebrovascular and pancreatitis/pancreatic cancer) such as iguanids, Sulfonamides urea, Alpha_glucosidase inhibitors, Thiazolidinones, DPP-4, others
5th				Safety of asthma treatments (long acting B-agonists)
	· · · · · · · · · · · · · · · · · · ·			



EMA priority safety topics (Dec 2010)

- Drug-induced Progressive Multifocal Leukoencephalopathy (PML).
- Long term safety of antipsychotic medication in patients with dementia
- Long term adverse skeletal effects of bisphosphonates.
- DNA collection and studies on the genetic causes of adverse drug reactions: angiotensin-converting enzyme inhibitors and angioedema, and statin-induced myopathy.
- Proton Pump Inhibitors and risk of myocardial infarction

However, no funding into Activity 4.2 'Responding to EU policy needs' foreseen in 2012 Work Programme!



How to learn about appropriate openings



- Go to FP7 health website at: <u>http://cordis.europa.eu/fp7/health/home_en.html</u>
- Consult the Health Work Programme (currently 2012, 6th Call)
- Consult the open Health Calls (via EC' Research Participants Portal):
 - FP7-HEALTH-2012-INNOVATION-1 (34 topics, €546m)
 - FP7-HEALTH-2012-INNOVATION-2 (3 topics, €108m)
- Automatic notification through CORDIS e-mail alert system (<u>http://cordis.europa.eu/guidance/e-mail-notification_en.html</u>)
 - All calls of interest.
 - Advance notice of calls that are imminent.



Application & evaluation & selection



Basic principles:

- Annual calls for proposals
- 2-stage application process: 1) short proposal; 2) full proposal
- Evaluation
 - by independent experts (overseen by independent observers)
 - 3 criteria:
 - Science & Technology excellence
 - Implementation & Management
 - Potential Impact
- Feedback: Evaluation Summary Reports (ESRs)



General conditions for participation



- Any research organisation can participate, including larger companies, as well as service-providers.
- Different funding levels:
 - For academia & SMEs: 75% of research costs
 - For larger companies: 50% of research costs
 - all 100% management & training & eligible IP costs
- FP7 is fully open to international cooperation

General conditions for participation



MUST: 3 partners from 3 EU or associated countries + ...

• the 27 EU Member States:

Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden, the United Kingdom.

the 13 Associated Countries:

Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey and the Faroe Islands.

 In addition, researchers from anywhere in the world can participate: e.g.: USA, India, Russia, China, South-Africa, Canada, Tanzania, Australia, Brazil, Ghana, Uganda, Kenya, Korea, Japan, Mexico... and in many cases, they can receive EU funding.

US participants in FP7 Health



Institution	Number of projects	Total EC contribution (~€ M)
Penn State	3	1.6
Johns Hopkins	2	1.3
Stanford	2	1.1
Duke	3	1.0
Jackson Laboratory	2	0.9
University of California	3	0.7
Brigham and Women's Hosp.	2	0.7
Harvard College	3	0.7
Other*	71	15.5
Total	91	23.5

* including: Dana Faber, Yale, Tufts, Sloan-Kettering, ISB, Soma Logic, Mayo Clinic, Novocell, Repligen, Parmatrope...

14



Now and beyond 2013

- Multiannual Financial Framework 2014-2020
- Future funding programmes to focus on *Europe 2020* priorities (already impacting on remaining FP7 calls)
 - Increase investment into R&D and innovation up to 3% GDP by 2020
 - Innovation Union (cross-portfolio initiative) ⇒ recent funding boost of 7 bn EUR under FP7 to tackle 'innovation deficit'

Future priorities - push for innovation

Europe 2020/Innovation Union

- address societal key challenges (e.g. ageing population);
- further strengthen scientific excellence/performance in Europe;
- reduce time to market; and
- bringing together public and private actors
 - bridging the gap between research and the market & ensure short and medium-term impact;

• EU Budget Review

- Common Strategic Framework
- Projects with a proven European added value
- More results-driven
- Leverage other public and private funding sources



- Official FP7 webpage (CORDIS): <u>http://cordis.europa.eu/fp7/health/</u>
- Dedicated Health Site: <u>http://cordis.europa.eu/fp7/health</u>
- Participant portal: <u>http://ec.europa.eu/research/participants/portal</u>
- To register as an Expert: https://cordis.europa.eu/emmfp7/

Get support:

- General: <u>http://cordis.europa.eu/fp7/health/support_en.html</u>
- National Contact Points: http://cordis.europa.eu/fp7/ncp_en.html